{"organizations": [], "uuid": "e336d68651e24ad3ee2083a3efde544df4535c12", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-novartis-announces-nejm-publicatio/brief-novartis-announces-nejm-publication-of-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-with-kymriah-in-children-young-adults-with-r-r-all-idUSFWN1PQ1G6", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis Announces NEJM Publication Of Updated Analysis From Eliana Trial Showing Longer-Term Durable Remissions With Kymriah In Children, Young Adults With R/R ALL", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.932, "site_type": "news", "published": "2018-02-01T06:20:00.000+02:00", "replies_count": 0, "uuid": "e336d68651e24ad3ee2083a3efde544df4535c12"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novartis-announces-nejm-publicatio/brief-novartis-announces-nejm-publication-of-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-with-kymriah-in-children-young-adults-with-r-r-all-idUSFWN1PQ1G6", "ord_in_thread": 0, "title": "BRIEF-Novartis Announces NEJM Publication Of Updated Analysis From Eliana Trial Showing Longer-Term Durable Remissions With Kymriah In Children, Young Adults With R/R ALL", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 31 (Reuters) - Novartis AG:\n* NOVARTIS ANNOUNCES NEJM PUBLICATION OF UPDATED ANALYSIS FROM ELIANA TRIAL SHOWING LONGER-TERM DURABLE REMISSIONS WITH KYMRIAH™ IN CHILDREN, YOUNG ADULTS WITH R/R ALL\n* NOVARTIS AG - ‍IN ANALYSIS OF 75 INFUSED PATIENTS WITH 3 OR MORE MONTHS OF FOLLOW-UP, KYMRIAH DEMONSTRATED AN OVERALL REMISSION RATE OF 81%​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-01T06:20:00.000+02:00", "crawled": "2018-02-01T06:09:57.812+02:00", "highlightTitle": ""}